Answers are grounded in this paper and cite their sources.
Post hoc analysis evaluates home infusion safety of cipa and mig in adults with late-onset Pompe disease, suggesting it is safe.
Background: Late-onset Pompe disease (LOPD) is caused by a deficiency of the acid α-glucosidase enzyme. In LOPD treatment, enzyme replacement therapy is delivered via intravenous infusion, typically in clinical settings. Cipaglucosidase alfa is delivered with the oral enzyme stabilizer miglustat (cipa + mig). Objectives: Evaluate the safety of cipa + mig home infusions. Design: Post hoc analysis of pooled safety data from three clinical trials in adults with LOPD (NCT02675465, NCT03729362, NCT04138277). Methods: The frequency and severity of infusion-associated reactions (IARs) during cipa + mig home and clinic administration were analyzed. Results: In total, 65/151 patients (43.0%) received ⩾1 cipa + mig home treatment. Of 9185 treatments, 2024 (22.0%) were administered at home. IAR frequency was similar for home (1.3%, 26/2024) and clinic (1.8%, 129/7161). The most frequent IAR following home infusion was pyrexia (6.2% of patients). Two patients with ⩾1 home-based treatment experienced serious IARs. Conclusion: Analyses support the safety of home cipa + mig treatment in eligible adults with LOPD.
No takes yet. Share an insight, caveat, or question.
Andersen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: